About this trial
The main objective of the genetic newborn screening part of the Screen4Care-project is to shorten the path to rare disease diagnosis and to facilitate early intervention. Therefore, genetic newborn screening for currently treatable rare diseases (TREAT-panel approach) will be offered to families expecting a baby. Whole genome sequencing (WGS) will be offered as additional diagnostic approach to newborns participating in Screen4Care TREAT-panel approach, if they develop symptoms suggestive of a genetic disease.
To evaluate to what extend genetic newborn screening has an impact on participating infants and their families, a follow-up with standardised questionnaires will be performed for all participating families.
Eligibility criteria
Qualifiers
newborns
Infants born in one of the participating hospitals and birth centres
Informed consent signed by both parents/legal guardian to participate in genetic newborn screening (TREAT-panel)
Participation in the TREAT-panel study
Disqualifiers
Missing informed consent of parents/legal guardian
Trial design
Treatments tested in this trial
- newborn genetic screening and whole genome sequencing
Treatment groups
Sponsors and collaborators
University Hospital Freiburg
Lead sponsor
Innovative Medicines Initiative
Collaborator
Università degli Studi di Ferrara
Collaborator
Ospedale Pediatrico Bambin Gesù
Collaborator
University of Siena
Collaborator
Centre Hospitalier Universitaire Dijon
Collaborator
Real Genix
Collaborator
University Hospital Goettingen
Collaborator
Centro Nacional de Análisis Genómico
Collaborator
Genoox
Collaborator
Municipal Hospital Karlsruhe
Collaborator
Schwarzwald-Baar Hospital
Collaborator
Illumina, Inc.
Collaborator
Charite University, Berlin, Germany
Collaborator
Brno University Hospital
Collaborator
General Hospital Of Thessaloniki Ippokratio
Collaborator
San Camillo Hospital, Rome
Collaborator
University of Rzeszow
Collaborator
Hospital San Pietro Fatebenefratelli
Collaborator